Eli Lilly (NYSE:LLY) inks an agreement with
Shanghai-based Junshi Biosciences to co-develop therapeutics antibodies
for the potential treatment and prevention of COVID-19.
Junshi’s lead program appears to be JS016, a fully
human recombinant monoclonal neutralizing antibody that binds to the
SARS-CoV-2 spike protein receptor-binding domain, effectively blocking
the coronavirus’ ability to bind to the ACE2 receptor on the surface of
healthy cells (binding to ACE2 is the first step in the infection
process).
Under the terms of the deal, Lilly will receive an
exclusive license to develop, manufacture and distribute products
outside of Greater China where Junshi will retain full rights.
Lilly plans to file an IND in the U.S. this
quarter. Junshi is in talks with China’s National Medical Products
Administration with the aim of starting clinical studies there.
https://seekingalpha.com/news/3568205-lilly-teams-up-junshi-bio-to-develop-covidminus-19-treatments
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.